First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
暂无分享,去创建一个
D. Hong | T. Yap | R. Latek | E. Yilmaz | V. Chiu | O. Rixe | D. Grebennik | S. Sahebjam | A. Collaku | Yi Liu | S. Efuni | Tomonori Tayama | Eniola Ogunmefun